Longitudinal multi-omics analyses identify responses of megakaryocytes, erythroid cells, and plasmablasts as hallmarks of severe COVID-19
Authors
- J.P. Bernardes
- N. Mishra
- F. Tran
- T. Bahmer
- L. Best
- J.I. Blase
- D. Bordoni
- J. Franzenburg
- U. Geisen
- J. Josephs-Spaulding
- P. Köhler
- A. Künstner
- E. Rosati
- A.C. Aschenbrenner
- P. Bacher
- N. Baran
- T. Boysen
- B. Brandt
- N. Bruse
- J. Dörr
- A. Dräger
- G. Elke
- D. Ellinghaus
- J. Fischer
- M. Forster
- A. Franke
- S. Franzenburg
- N. Frey
- A. Friedrichs
- J. Fuß
- A. Glück
- J. Hamm
- F. Hinrichsen
- M.P. Hoeppner
- S. Imm
- R. Junker
- S. Kaiser
- Y.H. Kan
- R. Knoll
- C. Lange
- G. Laue
- C. Lier
- M. Lindner
- G. Marinos
- R. Markewitz
- J. Nattermann
- R. Noth
- P. Pickkers
- K.F. Rabe
- A. Renz
- C. Röcken
- J. Rupp
- A. Schaffarzyk
- A. Scheffold
- J. Schulte-Schrepping
- D. Schunk
- D. Skowasch
- T. Ulas
- K.P. Wandinger
- M. Wittig
- J. Zimmermann
- H. Busch
- B.F. Hoyer
- C. Kaleta
- J. Heyckendorf
- M. Kox
- J. Rybniker
- S. Schreiber
- J.L. Schultze
- P. Rosenstiel
Journal
- Immunity
Citation
- Immunity 53 (6): 1296-1314
Abstract
Temporal resolution of cellular features associated with a severe COVID-19 disease trajectory is needed for understanding skewed immune responses and defining predictors of outcome. Here, we performed a longitudinal multi-omics study using a two-center cohort of 14 patients. We analyzed the bulk transcriptome, bulk DNA methylome, and single-cell transcriptome (>358,000 cells, including BCR profiles) of peripheral blood samples harvested from up to 5 time points. Validation was performed in two independent cohorts of COVID-19 patients. Severe COVID-19 was characterized by an increase of proliferating, metabolically hyperactive plasmablasts. Coinciding with critical illness, we also identified an expansion of interferon-activated circulating megakaryocytes and increased erythropoiesis with features of hypoxic signaling. Megakaryocyte- and erythroid-cell-derived co-expression modules were predictive of fatal disease outcome. The study demonstrates broad cellular effects of SARS-CoV-2 infection beyond adaptive immune cells and provides an entry point toward developing biomarkers and targeted treatments of patients with COVID-19.